Literature DB >> 19786996

Chemotherapy: Topotecan or treosulfan--that is the question.

Maurie Markman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19786996     DOI： 10.1038/nrclinonc.2009.144

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  4 in total

Review 1.  Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer.

Authors:  Allan Covens; Mark Carey; Peter Bryson; Shailendra Verma; Michael Fung Kee Fung; Mary Johnston
Journal:  Gynecol Oncol       Date:  2002-04       Impact factor: 5.482

Review 2.  Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses.

Authors:  Laurie Elit; Thomas K Oliver; Allan Covens; Janice Kwon; Michael Fung-Kee Fung; Holger W Hirte; Amit M Oza
Journal:  Cancer       Date:  2007-02-15       Impact factor: 6.860

3.  Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).

Authors:  Werner Meier; Andreas du Bois; Alexander Reuss; Walther Kuhn; Sigrid Olbricht; Martina Gropp; Barbara Richter; Hans-Joachim Lück; Rainer Kimmig; Jacobus Pfisterer
Journal:  Gynecol Oncol       Date:  2009-05-14       Impact factor: 5.482

Review 4.  Pharmaceutical management of ovarian cancer : current status.

Authors:  Maurie Markman
Journal:  Drugs       Date:  2008       Impact factor: 9.546
  4 in total
  1 in total

1.  DNA damage repair promotion in colonic epithelial cells by andrographolide downregulated cGAS‒STING pathway activation and contributed to the relief of CPT-11-induced intestinal mucositis.

Authors:  Yuanyuan Wang; Bin Wei; Danping Wang; Jingjing Wu; Jianhua Gao; Haiqing Zhong; Yang Sun; Qiang Xu; Wen Liu; Yanhong Gu; Wenjie Guo
Journal:  Acta Pharm Sin B       Date:  2021-04-29       Impact factor: 11.413
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.